Yayınlar & Eserler

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.

Yerlikaya A. , Kanbur E., Stanley B. A. , Tümer E.
Anti-cancer agents in medicinal chemistry, cilt.21, ss.20-32, 2021 (SCI Expanded İndekslerine Giren Dergi) identifier identifier

The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.

Yerlikaya A. , Kanbur E.
Current drug targets, 2020 (SCI Expanded İndekslerine Giren Dergi) identifier

An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line

Yerlikaya A. , Okur E.
CYTOTECHNOLOGY, cilt.72, sa.1, ss.121-130, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis

Okur E., Yerlikaya A.
CELL BIOLOGY AND TOXICOLOGY, cilt.35, sa.1, ss.33-47, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Secretomes reveal several novel proteins as well as TGF-beta 1 as the top upstream regulator of metastatic process in breast cancer

ERİN N., Ogan N., YERLİKAYA A.
BREAST CANCER RESEARCH AND TREATMENT, cilt.170, sa.2, ss.235-250, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line

DÜZGÜN Ş. A. , YERLİKAYA A. , ZEREN S. , BAYHAN Z., OKUR E., BOYACI İ.
CYTOTECHNOLOGY, cilt.69, sa.4, ss.711-724, 2017 (SCI İndekslerine Giren Dergi) Creative Commons License identifier identifier identifier

A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib

YERLİKAYA A. , Erdoğan E., OKUR E., Yerlikaya Ş., SAVRAN B.
ONCOLOGY LETTERS, cilt.12, sa.1, ss.323-330, 2016 (SCI İndekslerine Giren Dergi) Creative Commons License identifier identifier identifier

Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.

Aras B. , Yerlikaya A.
Oncology letters, cilt.11, ss.3179-3184, 2016 (SCI Expanded İndekslerine Giren Dergi) Creative Commons License identifier identifier identifier

A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line

YERLİKAYA A. , OKUR E., BAYKAL A. T. , Acılan C., BOYACI İ., ULUKAYA E.
JOURNAL OF PROTEOMICS, cilt.113, ss.315-325, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Data for a proteomic analysis of p53 independent induction of apoptosis by bortezomib

YERLİKAYA A. , OKUR E., BAYKAL A. T. , Acilan C., BOYACI İ., ULUKAYA E.
DATA IN BRIEF, cilt.1, ss.56-59, 2014 (SCI Expanded İndekslerine Giren Dergi) identifier

Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro

ULUKAYA E., Sarimahmut M., CEVATEMRE B., Ari F., YERLİKAYA A. , Dimas K.
BIOMEDICINE & PHARMACOTHERAPY, cilt.68, sa.4, ss.477-482, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells

SAVRAN B., YERLİKAYA A. , Erdoğan E., GENÇ O.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.14, sa.3, ss.466-472, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Evaluation of whether the ACE gene I/D polymorphism constitutes a risk factor for chronic obstructive pulmonary disease in the Turkish population

AYADA C. , TORU Ü., GENÇ O., YERLİKAYA A. , ŞAHİN S., TURGUT S., et al.
GENETICS AND MOLECULAR RESEARCH, cilt.13, sa.4, ss.10427-10433, 2014 (SCI İndekslerine Giren Dergi) Creative Commons License identifier identifier identifier

Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16f10 melanoma cell line

Koçak F. E. , Erdoğan E., Özyiğit F. , Yerlikaya A.
Cellular And Molecular Biology, cilt.59, ss.1894-1898, 2013 (SCI Expanded İndekslerine Giren Dergi) Creative Commons License identifier identifier

The Significance of Ubiquitin Proteasome Pathway in Cancer Development

YERLİKAYA A. , Yontem M.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, cilt.8, sa.3, ss.298-309, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells

YERLİKAYA A. , Altikat S. , Irmak R., Cavga F. Z. , Kocacan S., BOYACI İ.
MOLECULAR MEDICINE REPORTS, cilt.8, sa.1, ss.277-281, 2013 (SCI İndekslerine Giren Dergi) Creative Commons License identifier identifier identifier

Expression of Heme Oxygenase-1 in Response to Proteasomal Inhibition

YERLİKAYA A.
PROTEIN AND PEPTIDE LETTERS, cilt.19, sa.12, ss.1330-1333, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib

YERLİKAYA A. , OKUR E., ULUKAYA E.
TUMOR BIOLOGY, cilt.33, sa.5, ss.1385-1392, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Investigation of the eIF2 alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells

Yerlikaya A. , Dokudur H.
MOLECULAR BIOLOGY, cilt.44, sa.5, ss.760-768, 2010 (SCI İndekslerine Giren Dergi) identifier identifier

Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16FIO melanoma cell line

YERLİKAYA A. , OKUR E., Seker S., ERİN N.
MOLECULAR MEDICINE REPORTS, cilt.3, sa.2, ss.333-339, 2010 (SCI İndekslerine Giren Dergi) identifier identifier

Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade

YERLİKAYA A. , ERİN N.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, cilt.22, sa.6, ss.817-823, 2008 (SCI İndekslerine Giren Dergi) Creative Commons License identifier identifier identifier

Phosphorylation of eIF2 alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase

YERLİKAYA A. , Kimball S., Stanley B. A.
BIOCHEMICAL JOURNAL, cilt.412, ss.579-588, 2008 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Variations in fatty acids composition of pikeperch (Sander lucioperca) liver with respect to gonad maturation

UYSAL K., YERLİKAYA A. , Aksoylar M., YÖNTEM M., ULUPINAR M.
ECOLOGY OF FRESHWATER FISH, cilt.15, sa.4, ss.441-445, 2006 (SCI İndekslerine Giren Dergi) identifier identifier

Structural basis for the inactivation of AdoMetDC K12R mutant

YERLİKAYA A. , Stanley B. A.
PROTEIN AND PEPTIDE LETTERS, cilt.13, sa.3, ss.313-317, 2006 (SCI İndekslerine Giren Dergi) identifier identifier identifier

S-Adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination

YERLİKAYA A. , Stanley B. A.
JOURNAL OF BIOLOGICAL CHEMISTRY, cilt.279, sa.13, ss.12469-12478, 2004 (SCI İndekslerine Giren Dergi) Creative Commons License identifier identifier identifier

Diğer Dergilerde Yayınlanan Makaleler

Proteozom inhibitörü MG132 nin 4T1 meme ve B16F10 melanoma kanser hücrelerindeki sitotoksik etkileri

YERLİKAYA A. , Dokudur H., Şeker S.
Dumlupınar Üniversitesi Fen Bilimleri Dergisi, cilt.19, ss.15-22, 2009 (Diğer Kurumların Hakemli Dergileri)

Protein yıkımının önemi

YERLİKAYA A. , Dokudur H.
Uludağ Üniversitesi Tıp Fakültesi Dergisi, cilt.35, ss.93-99, 2009 (Diğer Kurumların Hakemli Dergileri)

Polyamines and S adenosylmethionine decarboxylase a polyamine biosynthetic enzyme

YERLİKAYA A.
Turkish Journal of Biochemistry, cilt.29, ss.208-214, 2004 (Diğer Kurumların Hakemli Dergileri)

Cellular functions of the 26S proteasome

YERLİKAYA A.
Turkish Journal of Biology, cilt.28, ss.31-38, 2004 (Diğer Kurumların Hakemli Dergileri)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

26S Proteozom Inhibitörü Bortezomibe Dirençli Prostat Hücre Hattı ve Direnç Mekanizmaları

Kanbur E., Tümer E., Budak F., Yerlikaya A.
25. Ulusal İmmünoloji Kongresi, Bursa, Türkiye, 20 - 22 Kasım 2020, ss.5-6 Creative Commons License

Proteozom inhibitörü carfilzomib’in vinkristin ve karboplatin ile Y79 retinoblastom hücre hattı üzerindeki in vitro etkinliklerinin karşılaştırılması.

AKTAŞ S., OKUR E., YERLİKAYA A. , AKTAŞ H., ÖZCURA F.
TOD 51. Ulusal Oftalmoloji Kongresi, Türkiye, 24 - 29 Ekim 2017

Kanser Araştırmalarında Proteomik Yaklaşımlar, Deneysel Modeller ve Getirileri

YERLİKAYA A. , OKUR E.
24. Ulusal Farmakoloji Kongresi, Türkiye, 17 - 20 Ekim 2017

Comparisons of metastatic and non-metastatic breast carcinoma cells using proteomic analysis of exosomes reveals increased secretion of BMP-1, fibulin4 and TGF-B1

Ogan N., YERLİKAYA A. , ERİN N.
3rd Congress of the Serbian Association for Cancer Research, Belgrade, Sırbistan Ve Karadağ, 6 - 07 Ekim 2017, ss.55-56

Proteozom İnhibitörü Bortezomibe Dirençli Prostat PC-3 Kanseri Hücresi

YEŞİLMEN B., YERLİKAYA A. , OKUR E.
17. ULUSAL MARMARA ÜNİVERSİTESİ TIP ÖĞRENCİ KONGRESİ, Türkiye, 12 - 14 Mayıs 2017

Increased Expression of TGF 1 and TSLP in Highly Metastatic Breast Cancer Cell Lines

Yitiz N., YERLİKAYA A. , ERİN N.
6. Multidisipliner Kanser Araştırma Kongresi, Konya, Türkiye, 27 - 30 Ekim 2016

Effects of p38 MAP kinase inhibitors on MDA MB 231 cell line

DÜZGÜN Ş. A. , YERLİKAYA A. , ZEREN S., BAYHAN Z., OKUR E.
41st FEBS Congress, 3 - 08 Eylül 2016

Comparisons of metastatic and non metastatic breast carcinoma cells using proteomic analysis of exosomes

ERİN N., YERLİKAYA A.
41st FEBS Congress, 3 - 08 Eylül 2016

The effect of season on liver fatty acids of pikeperch Sander lucioperca from lake Eğirdir Turkey

UYSAL K., YERLİKAYA A. , Aksoylar M., YÖNTEM M., ULUPINAR M.
II: International Natural Protection Symposium, 8 - 10 Eylül 2005

Apoptotic mechanism of a new combination involving bortezomib and GRP78 inhibitor BAPTA on 4T1 cancer cells

Yerlikaya Ş., OKUR E., YERLİKAYA A.
3rd Anticancer Agent Development Congress, 18 - 19 Mayıs 2015

Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16F10 melanoma cell line

KOÇAK F. E. , Erdoğan E., Özyiğit F., YERLİKAYA A.
Kongre & Lab Expo 2014, 16 - 20 Eylül 2014 identifier identifier

The antiproliferation and antitumor activities of the 26S proteasome inhibitors

YERLİKAYA A. , ERİN N.
Joint 4th EORTC Pathobiology Group Annual Meeting & 1st International Multidisciplinary Cancer Research Congress, 21 - 24 Mayıs 2009

The 26S proteasome one of the most critical players in cancer development

YERLİKAYA A.
The EACR-Sponsored 2nd Anticancer Agents Congress: Targeting Cancer Stem Cells, 23 - 25 Nisan 2014

Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro

SARIMAHMUT M., CEVATEMRE B., ARI F., YERLİKAYA A. , Dimas K., ULUKAYA E.
The EACR-Sponsored 2nd Anticancer Agents Congress: Targeting Cancer Stem Cells, 23 - 25 Nisan 2014 identifier identifier identifier

Targeting the proteasome for the induction of apoptosis in cancer treatment

YERLİKAYA A.
EACR-Anticancer Agents Research Congress, 13 - 16 Ekim 2011

Effect of proteasome inhibition on protein synthesis and eIF 2 phosphorylation

YERLİKAYA A.
1. Multidisipliner Kanser Araştırma Sempozyumu (uluslararası katılımlı), 12 - 15 Mart 2006

Kitap & Kitap Bölümleri

Bölüm G - Beyin

YERLİKAYA A.
İnsan Fizyolojisi, Addurrahman Aktümsek, Editör, Nobel Yayınevi, ss.193-232, 2010

Protein sentezi ve yıkımı

YERLİKAYA A.
Moleküler Biyoloji, Ahmet Yıldırım, Fevzi Bardakçı, Mehmet Karataş, Bahattin Tanyolaç , Editör, Nobel Yayınevi, ss.219-246, 2007